Maxion Therapeutics Raises $72 million (£58 million) in an Oversubscribed Series A Financing to Advance its KnotBody® Pipeline and Platform
Maxion Therapeutics Raises $72 million (£58 million) in an Oversubscribed Series A Financing to Advance its KnotBody® ...
The Pharma Letter14h
Maxion Therapeutics raises $72 million
Cambridge, UK-based biotech start-up Maxion Therapeutics, which is developing antibody-based KnotBody drugs for ion channel- ...
Business Weekly15h
International investors back Maxion Therapeutics in $72m Series A raise
Cambridge biotech Maxion Therapeutics has raised $72 million (£58m) in a Series A financing to further grow the business ...
Boehringer Ingelheim and Salipro enter drug discovery partnership
The partnership brings together Salipro’s tech for stabilising drug targets from Boehringer’s drug discovery programmes.
BioWorld4d
Grant supports evaluation of Myrobalan’s GPR17 antagonist for progressive MS
Myrobalan Therapeutics Inc. has been awarded a grant of over $850,000 from the National Multiple Sclerosis Society to support the preclinical and translational development of MRO-002, a ...
Salipro Biotech and Boehringer Ingelheim Enter Research and License Agreement to Accelerate Multiple Boehringer Ingelheim Pipeline Programs
Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license agreement with ...
The Joplin Globe4d
Myrobalan Therapeutics Awarded a Grant from the National Multiple Sclerosis Society to Advance Development of MRO-002 in Multiple Sclerosis
Myrobalan Therapeutics, a biotechnology company developing potent, selective, and brain-penetrant oral small-molecule therapies to restore brain function, today announced a grant of over $850,000 from ...
Knowridge Science Report5d
Study shows surprising link between gut health and high blood pressure
Researchers at Monash University have uncovered how the gut—and the food we eat—affects high blood pressure. Their discovery ...